美国安进地舒单抗注射液的价格贵不贵

Xgeva is a human RANKL monoclonal antibody (IgG2) with high affinity and specificity. Desosumab Xgeva can bind to and act on RANKL, hindering the binding of RANKL on the surface of osteoclast precursor cells and mature cells, thereby inhibiting osteoclast activation and development, reducing bone resorption, and increasing bone density. Desosumab Xgeva was approved for marketing in the United States in 2010.

The original drug of denosumab Xgeva was developed by Amgen in the United States and is currently approved for multiple indications around the world. Amgen Biopharmaceutical Company (Amgen) is the world's leading innovative biopharmaceutical R&D and manufacturing company. It takes "drug innovation" as its core concept and attaches great importance to the accumulation of R&D capabilities. It has achieved major breakthroughs in the fields of human genome, tumor biology, neuroscience, hematology and other fields.

Is Amgen denosumab injection expensive in the United States?

Desosumab Xgeva produced by Amgen Biopharmaceuticals in the United States is exported to China. Specification: 120mg/1.7ml bottle/box. Pharmacy price: RMB 5,298.00. Desosumab Xgeva produced by Amgen Biopharmaceuticals in the United States has the specifications in the United States: 60mg/1ml tube/box, price: US$1,169.98. 

The denosumab Xgeva produced by Amgen Biopharmaceuticals in the United States is exported to Turkey in 120 mg and sells for about $1,500. Since the exchange rate floating price is not fixed, if patients want to know the specific price information of denosumab Xgeva, they can consult the medical companion travel service.

Treatment with Xgeva may lead to hypocalcemia. Although the overall incidence of hypocalcemia during the use of denosumab Xgeva is low, patients with renal insufficiency should monitor and correct blood calcium levels before and after starting denosumab Xgeva treatment, and may add calcium and vitamin D as a preventive measure.

Recommended related hot articles: /newsDetail/91043.html